Comparing the efficacy and safety of dolutegravir+lamivudine vs bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens in a multicenter cohort
Similar Efficacy, Safety and CD4 T cell increase up to Week 96 observed in Fostemsavir (FTR) based regimens from the BRIGHTE study and Dolutegravir (DTG) based regimens from the VIKING-3 study in multidrug resistant (MDR) HIV-1 individuals
Real-world data on the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH): 24-month full dataset results of the Italian BICSTaR cohort
Abstract